Stock Scorecard
Stock Summary for Royalty Pharma plc - Class A (RPRX) - $36.36 as of 9/12/2025 9:22:36 PM EST
Total Score
10 out of 30
Safety Score
56 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RPRX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RPRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RPRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RPRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for RPRX (56 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 4 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 8 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for RPRX
Financial Details for RPRX
Company Overview |
|
|---|---|
| Ticker | RPRX |
| Company Name | Royalty Pharma plc - Class A |
| Country | USA |
| Description | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/5/2025 |
Stock Price History |
|
| Last Day Price | 36.36 |
| Price 4 Years Ago | 36.30 |
| Last Day Price Updated | 9/12/2025 9:22:36 PM EST |
| Last Day Volume | 3,652,376 |
| Average Daily Volume | 3,718,469 |
| 52-Week High | 37.97 |
| 52-Week Low | 23.59 |
| Last Price to 52 Week Low | 54.13% |
Valuation Measures |
|
| Trailing PE | 15.80 |
| Industry PE | 21.34 |
| Sector PE | 40.86 |
| 5-Year Average PE | 10.43 |
| Free Cash Flow Ratio | 24.90 |
| Industry Free Cash Flow Ratio | 13.20 |
| Sector Free Cash Flow Ratio | 29.37 |
| Current Ratio Most Recent Quarter | 1.26 |
| Total Cash Per Share | 1.46 |
| Book Value Per Share Most Recent Quarter | 14.68 |
| Price to Book Ratio | 2.46 |
| Industry Price to Book Ratio | 28.96 |
| Sector Price to Book Ratio | 32.27 |
| Price to Sales Ratio Twelve Trailing Months | 9.15 |
| Industry Price to Sales Ratio Twelve Trailing Months | 44.01 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.72 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 432,293,000 |
| Market Capitalization | 15,718,173,480 |
| Institutional Ownership | 82.44% |
Dividends |
|
| Ex-Dividend Date | 8/15/2025 |
| Previous Dividend Amount | 0.2200 |
| Current Dividend Amount | 0.2200 |
| Total Years Dividend Increasing | 5 |
| Trailing Annual Dividend Rate | 0.87 |
| Trailing Annual Dividend Yield | 2.38% |
| Forward Annual Dividend Rate | 0.88 |
| Forward Annual Dividend Yield | 2.41% |
| 5-Year Dividend Payments Count | 21 |
| 3-Year Average Dividend Yield | 3.36% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 4.76% |
| 3-Year Dividend Growth Rate Percentage | 2.35% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 7.30% |
| Dividend Payout Ratio | 37.99% |
Income Statement |
|
| Quarterly Earnings Growth YOY | -68.60% |
| Annual Earnings Growth | -24.31% |
| Reported EPS 12 Trailing Months | 2.29 |
| Reported EPS Past Year | 2.20 |
| Reported EPS Prior Year | 3.21 |
| Net Income Twelve Trailing Months | 1,020,726,000 |
| Net Income Past Year | 858,983,000 |
| Net Income Prior Year | 1,134,834,000 |
| Quarterly Revenue Growth YOY | 7.70% |
| 5-Year Revenue Growth | 4.52% |
| Operating Margin Twelve Trailing Months | 38.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 631,908,000 |
| Total Cash Past Year | 929,026,000 |
| Total Cash Prior Year | 477,010,000 |
| Net Cash Position Most Recent Quarter | -6,371,155,000 |
| Net Cash Position Past Year | -5,685,627,000 |
| Long Term Debt Past Year | 6,614,653,000 |
| Long Term Debt Prior Year | 6,135,285,000 |
| Total Debt Most Recent Quarter | 7,003,063,000 |
| Equity to Debt Ratio Past Year | 0.51 |
| Equity to Debt Ratio Most Recent Quarter | 0.48 |
| Total Stockholder Equity Past Year | 6,946,581,000 |
| Total Stockholder Equity Prior Year | 6,526,497,000 |
| Total Stockholder Equity Most Recent Quarter | 6,347,910,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 1,636,475,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 3.79 |
| Free Cash Flow Past Year | 2,768,986,000 |
| Free Cash Flow Prior Year | 872,280,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.02 |
| 20-Day Bollinger Lower Band | 31.93 |
| 20-Day Bollinger Middle Band | 35.09 |
| 20-Day Bollinger Upper Band | 38.25 |
| Beta | 0.57 |
| RSI | 49.97 |
| 50-Day SMA | 31.15 |
| 150-Day SMA | 30.27 |
| 200-Day SMA | 32.06 |
System |
|
| Modified | 9/11/2025 9:05:48 AM EST |